

Selection criteria of TKIs in 1L or 2L after atezolizumab+bevacizumab for advanced or unresectable HCC patients

80%



HCC

Advanced stage (BCLC C) • Portal invasion
Extrahepatic spread • Child-Pugh A-B • ECOG PS 1-2

20%



- Patients not eligible for atezo+bev:
- Organ transplantation
 - Severe auto-immune disease
 - High bleeding risk

First line

Atezolizumab + bevacizumab

Second line

Sorafenib or lenvatinib or regorafenib or cabozantinib or ramucirumab

Third line

Regorafenib or Cabozantinib or ramucirumab

First line



Sorafenib or lenvatinib?

Three decision points for consideration



Efficacy endpoints:

• Overall survival

mOS:

SHARP:

Sorafenib= 10.7 months vs Placebo= 7.9 months
HR: 0.69; 95% CI, 0.55-0.87 p<0.001

REFLECT:

Lenvatinib= 13.6 months (12.1–14.9) vs
sorafenib= 12.3 months (10.4–13.9)
HR (95% CI): 0.92 (0.79–1.06)

• Response rate

ORR, n (%)	mRECIST by investigator	mRECIST by independent review	RECIST v1.1 by independent review
lenvatinib	115 (24.1)	194 (40.6)	90 (18.8)
sorafenib	44 (9.2)	59 (12.4)	31 (6.5)



Safety endpoints:

- Patients comorbidities
- Need to know the list of relevant AEs

Adverse event, n (%)	lenvatinib (n=476) Grade 3/4	Sorafenib (n=475) Grade 3/4
Most frequent TEAES (>15%)		
Hypertension	111 (23)	68 (14)
Diarrhea	20 (4)	20 (4)
Decreased appetite	22 (5)	6 (1)
Decreased weight	36 (8)	14 (3)
Fatigue	18 (4)	17 (4)
Palmar-plantar erythrodysesthesia	14 (3)	54 (11)
Proteinuria	27 (6)	8 (2)
Dysphonia	1 (<1)	0 (0)
Nausea	4 (1)	4 (1)
Decreased platelet count	26 (6)	16 (3)
Abdominal pain	8 (2)	13 (3)
Vomiting	6 (1)	5 (1)
Constipation	3 (1)	0 (0)
Elevated aspartate aminotransferase	24 (5)	38 (8)



Patients characteristics:

- Tumours size
- Liver function

mOS sorafenib in GIDEON by liver function status:

- Child-Pugh A: 13.6 months; 95% C: (12.8-14.7)
- Child-Pugh B: 5.2 months; 95% C: (4.6-6.3)
 - B7: 6.2 months; 95% C: (4.9-8.7)
 - B8: 4.8 months; 95% C: (4.1-6.9)
 - B9: 3.7 months; 95% C: (3.0-5.1)

Abbreviations:

1L, first line; 2L, second line; AE, adverse event; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; HR, hazard ratio; mOS, median overall survival; ORR, objective response rate; (m)RECIST, (modified) response evaluation criteria in solid tumours; TEAES, treatment-emergent adverse events; TKI, tyrosine kinase inhibitor

References:

Finn RS et al. N Engl J Med. 2020;382(20):1894-905. Llovet JM et al. N Engl J Med. 2008;359(4):378-90.

Kudo M et al. Lancet. 2018;391(10126):1163-73. Kudo et al. ILCA 2021 Poster #P-34

Gordan JD et al. J Clin Oncol. 2020;43:17-4345. Vogel A et al. Ann Oncol. 2021;801-805